5 research outputs found
ΠΠ°Π»ΡΡΠΈΠ½Π΅Π²ΡΠΈΠ½ ΡΠΊ ΠΌΠ°ΡΠΊΠ΅Ρ Π³ΡΠΏΠ΅ΡΡΡΠΎΡΡΡ ΠΌΡΠΎΠΊΠ°ΡΠ΄Π° Ρ Π΄ΡΡΠ΅ΠΉ ΡΠ· ΠΊΠ»Π°ΠΏΠ°Π½Π½ΠΈΠΌΠΈ Π²ΡΠΎΠ΄ΠΆΠ΅Π½ΠΈΠΌΠΈ Π²Π°Π΄Π°ΠΌΠΈ ΡΠ΅ΡΡΡ
Aim. To identify interrelations between the calcineurin levels in children with valvular congenital heart diseases without heart failure and the echocardiography parameters of myocardial hypertrophy.Results: It was established the significantly decreased calcineurin level in congenial valvular heart diseases in children as well as an absence of correlations of the left ventricle myocardial mass and index with negative ones to the dimensions of right ventricle in comparison to healthy children ofΒ corresponding age.Conclusion: The obtained data testifies the importance of calcineurin system activity in the formation of pathologic myocardial hypertrophy in children with valvular congenital heart diseases and without manifestation of heart failure.Π‘ ΡΠ΅Π»ΡΡ ΠΈΠ·ΡΡΠ΅Π½ΠΈΡ Π²Π·Π°ΠΈΠΌΠΎΡΠ²ΡΠ·ΠΈ ΠΌΠ΅ΠΆΠ΄Ρ ΡΡΠΎΠ²Π½ΡΠΌΠΈ ΠΊΠ°Π»ΡΡΠΈΠ½Π΅Π²ΡΠΈΠ½Π° Π² ΡΡΠ²ΠΎΡΠΎΡΠΊΠ΅ ΠΊΡΠΎΠ²ΠΈ Π΄Π΅ΡΠ΅ΠΉ Ρ ΠΊΠ»Π°ΠΏΠ°Π½Π½ΡΠΌΠΈ Π²ΡΠΎΠΆΠ΄ΡΠ½Π½ΡΠΌΠΈ ΠΏΠΎΡΠΎΠΊΠ°ΠΌΠΈ ΡΠ΅ΡΠ΄ΡΠ° ΠΈ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΡΠΌΠΈ Π³ΠΈΠΏΠ΅ΡΡΡΠΎΡΠΈΠΈ ΠΌΠΈΠΎΠΊΠ°ΡΠ΄Π° ΠΏΠΎ Π΄Π°Π½Π½ΡΠΌ Π²Π½ΡΡΡΠΈΡΠ΅ΡΠ΄Π΅ΡΠ½ΠΎΠΉ Π³Π΅ΠΌΠΎΠ΄ΠΈΠ½Π°ΠΌΠΈΠΊΠΈ ΠΏΡΠΈ ΠΏΠΎΠΌΠΎΡΠΈ ΠΈΠΌΠΌΡΠ½ΠΎΡΠ΅ΡΠΌΠ΅Π½ΡΠ½ΠΎΠ³ΠΎ Π°Π½Π°Π»ΠΈΠ·Π° ΡΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½Ρ ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΠΈ ΠΊΠ°Π»ΡΡΠΈΠ½Π΅Π²ΡΠΈΠ½Π° Ρ Π΄Π΅ΡΠ΅ΠΉ Ρ ΠΊΠ»Π°ΠΏΠ°Π½Π½ΡΠΌΠΈ Π²ΡΠΎΠΆΠ΄Π΅Π½Π½ΡΠΌΠΈ ΠΏΠΎΡΠΎΠΊΠ°ΠΌΠΈ ΡΠ΅ΡΠ΄ΡΠ° Π±Π΅Π· ΠΏΡΠΈΠ·Π½Π°ΠΊΠΎΠ² ΡΠ΅ΡΠ΄Π΅ΡΠ½ΠΎΠΉ Π½Π΅Π΄ΠΎΡΡΠ°ΡΠΎΡΠ½ΠΎΡΡΠΈ ΠΈ Π²ΡΠΏΠΎΠ»Π½Π΅Π½ΠΎ ΡΠΎΠΏΠΎΡΡΠ°Π²Π»Π΅Π½ΠΈΠ΅ ΠΏΠΎΠ»ΡΡΠ΅Π½Π½ΡΡ
Π΄Π°Π½Π½ΡΡ
Ρ ΡΡ
ΠΎΠΊΠ°ΡΠ΄ΠΈΠΎΠ³ΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΠΌΠΈ ΠΏΠ°ΡΠ°ΠΌΠ΅ΡΡΠ°ΠΌΠΈ. Π£ΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½ΠΎ Π΄ΠΎΡΡΠΎΠ²Π΅ΡΠ½ΠΎΠ΅ ΡΠ½ΠΈΠΆΠ΅Π½ΠΈΠ΅ ΡΡΠ²ΠΎΡΠΎΡΠΎΡΠ½ΠΎΠΉ ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΠΈ ΠΊΠ°Π»ΡΡΠΈΠ½Π΅Π²ΡΠΈΠ½Π° ΠΏΡΠΈ Π²ΡΠΎΠΆΠ΄ΡΠ½Π½ΡΡ
ΠΊΠ»Π°ΠΏΠ°Π½Π½ΡΡ
ΠΏΠΎΡΠΎΠΊΠ°Ρ
, Π° ΡΠ°ΠΊΠΆΠ΅ ΠΎΡΡΡΡΡΡΠ²ΠΈΠ΅ ΠΊΠΎΡΡΠ΅Π»ΡΡΠΈΠΉ Ρ ΠΌΠ°ΡΡΠΎΠΉ ΠΌΠΈΠΎΠΊΠ°ΡΠ΄Π° ΠΈ ΠΈΠ½Π΄Π΅ΠΊΡΠΎΠΌ ΠΌΠ°ΡΡΡ ΠΌΠΈΠΎΠΊΠ°ΡΠ΄Π° Π»Π΅Π²ΠΎΠ³ΠΎ ΠΆΠ΅Π»ΡΠ΄ΠΎΡΠΊΠ° ΠΏΡΠΈ Π½Π°Π»ΠΈΡΠΈΠΈΠΈ Π½Π΅Π³Π°ΡΠΈΠ²Π½ΡΡ
ΠΊΠΎΡΡΠ΅Π»ΡΡΠΈΠΉ Ρ ΡΠ°Π·ΠΌΠ΅ΡΠ°ΠΌΠΈ ΠΏΡΠ°Π²ΠΎΠ³ΠΎ ΠΆΠ΅Π»ΡΠ΄ΠΎΡΠΊΠ° Π² ΡΡΠ°Π²Π½Π΅Π½ΠΈΠΈ ΡΠΎ Π·Π΄ΠΎΡΠΎΠ²ΡΠΌΠΈ Π΄Π΅ΡΡΠΌΠΈ ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²ΡΡΡΠ΅Π³ΠΎ Π²ΠΎΠ·ΡΠ°ΡΡΠ°, ΡΡΠΎ ΡΠ²ΠΈΠ΄Π΅ΡΠ΅Π»ΡΡΡΠ²ΠΎΠ²Π°Π»ΠΎ ΠΎ Π²Π°ΠΆΠ½ΠΎΠΉ ΡΠΎΠ»ΠΈ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΡΠΈΡΡΠ΅ΠΌΡ ΠΊΠ°Π»ΡΡΠΈΠ½Π΅Π²ΡΠΈΠ½Π° Π² ΡΠΎΡΠΌΠΈΡΠΎΠ²Π°Π½ΠΈΠΈ ΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠΉ Π³ΠΈΠΏΠ΅ΡΡΡΠΎΡΠΈΠΈ Ρ Π΄Π΅ΡΠ΅ΠΉ Ρ ΠΊΠ»Π°ΠΏΠ°Π½Π½ΡΠΌΠΈ Π²ΡΠΎΠΆΠ΄Π΅Π½Π½ΡΠΌΠΈ ΠΏΠΎΡΠΎΠΊΠ°ΠΌΠΈ ΡΠ΅ΡΠ΄ΡΠ° Π±Π΅Π· ΠΌΠ°Π½ΠΈΡΠ΅ΡΡΠ½ΡΡ
ΠΏΡΠΎΡΠ²Π»Π΅Π½ΠΈΠΉ ΡΠ΅ΡΠ΄Π΅ΡΠ½ΠΎΠΉ Π½Π΅Π΄ΠΎΡΡΠ°ΡΠΎΡΠ½ΠΎΡΡΠΈ.Π ΠΌΠ΅ΡΠΎΡ Π²ΠΈΠ²ΡΠ΅Π½Π½Ρ Π²Π·Π°ΡΠΌΠΎΠ·Π²βΡΠ·ΠΊΡΠ² ΠΌΡΠΆ ΡΡΠ²Π½ΡΠΌΠΈΒ ΠΊΠ°Π»ΡΡΠΈΠ½Π΅Π²ΡΠΈΠ½Ρ Ρ ΡΠΈΡΠΎΠ²Π°ΡΡΡ ΠΊΡΠΎΠ²Ρ Π΄ΡΡΠ΅ΠΉ ΡΠ· ΠΊΠ»Π°ΠΏΠ°Π½Π½ΠΈΠΌΠΈ Π²ΡΠΎΠ΄ΠΆΠ΅Π½ΠΈΠΌΠΈ Π²Π°Π΄Π°ΠΌΠΈ ΡΠ΅ΡΡΡ ΡΠ° ΠΏΠΎΠΊΠ°Π·Π½ΠΈΠΊΠ°ΠΌΠΈ ΠΌΡΠΎΠΊΠ°ΡΠ΄ΡΠ°Π»ΡΠ½ΠΎΡ Π³ΡΠΏΠ΅ΡΡΡΠΎΡΡΡ Π·Π° Π΄Π°Π½ΠΈΠΌΠΈ Π²Π½ΡΡΡΡΡΠ½ΡΠΎΡΠ΅ΡΡΠ΅Π²ΠΎΡ Π³Π΅ΠΌΠΎΠ΄ΠΈΠ½Π°ΠΌΡΠΊΠΈ Π·Π° Π΄ΠΎΠΏΠΎΠΌΠΎΠ³ΠΎΡ ΡΠΌΡΠ½ΠΎΡΠ΅ΡΠΌΠ΅Π½ΡΠ½ΠΎΠ³ΠΎ Π°Π½Π°Π»ΡΠ·Ρ Π²ΠΈΠ·Π½Π°ΡΠΈΠ»ΠΈ ΡΡΠ²Π½Ρ ΠΊΠ°Π»ΡΡΠΈΠ½Π΅Π²ΡΠΈΠ½Ρ Ρ Ρ
Π²ΠΎΡΠΈΡ
ΡΠ· ΠΊΠ»Π°ΠΏΠ°Π½Π½ΠΈΠΌΠΈ Π²ΡΠΎΠ΄ΠΆΠ΅Π½ΠΈΠΌΠΈ Π²Π°Π΄Π°ΠΌΠΈ ΡΠ΅ΡΡΡ Π±Π΅Π· ΠΎΠ·Π½Π°ΠΊ ΡΠ΅ΡΡΠ΅Π²ΠΎΡ Π½Π΅Π΄ΠΎΡΡΠ°ΡΠ½ΠΎΡΡΡ ΡΠ° Π²ΠΈΠΊΠΎΠ½Π°Π»ΠΈ Π·ΡΡΡΠ°Π²Π»Π΅Π½Π½Ρ Π΄Π°Π½ΠΈΡ
, ΡΠΎ ΠΎΠ΄Π΅ΡΠΆΠ°Π»ΠΈ, Π· Π΅Ρ
ΠΎΠΊΠ°ΡΠ΄ΡΠΎΠ³ΡΠ°ΡΡΡΠ½ΠΈΠΌΠΈ ΠΏΠ°ΡΠ°ΠΌΠ΅ΡΡΠ°ΠΌΠΈ. ΠΡΡΠ°Π½ΠΎΠ²ΠΈΠ»ΠΈ Π²ΡΡΠΎΠ³ΡΠ΄Π½Π΅ Π·Π½ΠΈΠΆΠ΅Π½Π½Ρ ΡΡΠ²Π½ΡΠ² ΠΊΠ°Π»ΡΡΠΈΠ½Π΅Π²ΡΠΈΠ½Ρ ΠΏΡΠΈ Π²ΡΠΎΠ΄ΠΆΠ΅Π½ΠΈΡ
ΠΊΠ»Π°ΠΏΠ°Π½Π½ΠΈΡ
Π²Π°Π΄Π°Ρ
ΡΠ΅ΡΡΡ, Π° ΡΠ°ΠΊΠΎΠΆΒ Π²ΡΠ΄ΡΡΡΠ½ΡΡΡΡ ΠΊΠΎΡΠ΅Π»ΡΡΡΠΉ ΡΠ· ΠΌΠ°ΡΠΎΡ ΠΌΡΠΎΠΊΠ°ΡΠ΄Π° ΡΠ° ΡΠ½Π΄Π΅ΠΊΡΠΎΠΌ ΠΌΠ°ΡΠΈ ΠΌΡΠΎΠΊΠ°ΡΠ΄Π° Π»ΡΠ²ΠΎΠ³ΠΎ ΡΠ»ΡΠ½ΠΎΡΠΊΠ° Π·Π° Π½Π°ΡΠ²Π½ΠΎΡΡΡ Π½Π΅Π³Π°ΡΠΈΠ²Π½ΠΈΡ
ΠΊΠΎΡΠ΅Π»ΡΡΡΠΉ ΡΠ· ΡΠΎΠ·ΠΌΡΡΠ°ΠΌΠΈ ΠΏΡΠ°Π²ΠΎΠ³ΠΎ ΡΠ»ΡΠ½ΠΎΡΠΊΠ° Π½Π° Π²ΡΠ΄ΠΌΡΠ½Ρ Π²ΡΠ΄ ΡΠΌΠΎΠ²Π½ΠΎ Π·Π΄ΠΎΡΠΎΠ²ΠΈΡ
Π΄ΡΡΠ΅ΠΉ Π²ΡΠ΄ΠΏΠΎΠ²ΡΠ΄Π½ΠΎΠ³ΠΎ Π²ΡΠΊΡ, ΡΠΎ ΡΠ²ΡΠ΄ΡΠΈΠ»ΠΎ ΠΏΡΠΎ Π²Π°ΠΆΠ»ΠΈΠ²ΡΡΡΡ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ ΡΠΈΡΡΠ΅ΠΌΠΈ ΠΊΠ°Π»ΡΡΠΈΠ½Π΅Π²ΡΠΈΠ½Ρ Π² ΡΠΎΡΠΌΡΠ²Π°Π½Π½Ρ ΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΡΡΠ½ΠΎΡ Π³ΡΠΏΠ΅ΡΡΡΠΎΡΡΡ Ρ Π΄ΡΡΠ΅ΠΉ ΡΠ· ΠΊΠ»Π°ΠΏΠ°Π½Π½ΠΈΠΌΠΈ Π²ΡΠΎΠ΄ΠΆΠ΅Π½ΠΈΠΌΠΈ Π²Π°Π΄Π°ΠΌΠΈ ΡΠ΅ΡΡΡ Π±Π΅Π· ΠΌΠ°Π½ΡΡΠ΅ΡΡΠ½ΠΈΡ
ΠΎΠ·Π½Π°ΠΊ ΡΠ΅ΡΡΠ΅Π²ΠΎΡ Π½Π΅Π΄ΠΎΡΡΠ°ΡΠ½ΠΎΡΡΡ
Calcineurin as a marker of myocardial hypertrophy in children with valvular congenital heart diseases
Aim. To identify interrelations between the calcineurin levels in children with valvular congenital heart diseases without heart failure and the echocardiography parameters of myocardial hypertrophy.
Results: It was established the significantly decreased calcineurin level in congenial valvular heart diseases in children as well as an absence of correlations of the left ventricle myocardial mass and index with negative ones to the dimensions of right ventricle in comparison to healthy children of corresponding age.
Conclusion: The obtained data testifies the importance of calcineurin system activity in the formation of pathologic myocardial hypertrophy in children with valvular congenital heart diseases and without manifestation of heart failure
Influenza Epidemiology And Influenza Vaccine Effectiveness During The 2016-2017 Season In The Global Influenza Hospital Surveillance Network (Gihsn)
BackgroundThe Global Influenza Hospital Surveillance Network (GIHSN) aims to determine the burden of severe influenza disease and Influenza Vaccine Effectiveness (IVE). This is a prospective, active surveillance and hospital-based epidemiological study to collect epidemiological data in the GIHSN. In the 2016-2017 influenza season, 15 sites in 14 countries participated in the GIHSN, although the analyses could not be performed in 2 sites. A common core protocol was used in order to make results comparable. Here we present the results of the GIHSN 2016-2017 influenza season.MethodsA RT-PCR test was performed to all patients that accomplished the requirements detailed on a common core protocol. Patients admitted were included in the study after signing the informed consent, if they were residents, not institutionalised, not discharged in the previous 30days from other hospitalisation with symptoms onset within the 7days prior to admission. Patients 5years old or more must also complied the Influenza-Like Illness definition. A test negative-design was implemented to perform IVE analysis. IVE was estimated using a logistic regression model, with the formula IVE=(1-aOR)x100, where aOR is the adjusted Odds Ratio comparing cases and controls.ResultsAmong 21,967 screened patients, 10,140 (46.16%) were included, as they accomplished the inclusion criteria, and tested, and therefore 11,827 (53.84%) patients were excluded. Around 60% of all patients included with laboratory results were recruited at 3 sites. The predominant strain was A(H3N2), detected in 63.6% of the cases (1840 patients), followed by B/Victoria, in 21.3% of the cases (618 patients). There were 2895 influenza positive patients (28.6% of the included patients). A(H1N1)pdm09 strain was mainly found in Mexico. IVE could only be performed in 6 sites separately. Overall IVE was 27.24 (95% CI 15.62-37.27. Vaccination seemed to confer better protection against influenza B and in people 2-4years, or 85years old or older. The aOR for hospitalized and testing positive for influenza was 3.02 (95% CI 1.59-5.76) comparing pregnant with non-pregnant women.ConclusionsVaccination prevented around 1 in 4 hospitalisations with influenza. Sparse numbers didn't allow estimating IVE in all sites separately. Pregnancy was found a risk factor for influenza, having 3 times more risk of being admitted with influenza for pregnant women.Wo